University of Texas MD Anderson Cancer Center

OpenWorks @ MD Anderson
OncoLog MD Anderson's Report to Physicians
(All issues)

OncoLog MD Anderson's Report to Physicians

7-2000

OncoLog Volume 45, Number 07/08, July/August 2000
Kerry L. Wright
The University of Texas MD Anderson Cancer Center

Dawn Chalaire
The University of Texas MD Anderson Cancer Center

Rebecca D. Pentz PhD
The University of Texas MD Anderson Cancer Center

Follow this and additional works at: https://openworks.mdanderson.org/oncolog
Part of the History of Science, Technology, and Medicine Commons, and the Oncology Commons

Recommended Citation
Wright, Kerry L.; Chalaire, Dawn; and Pentz, Rebecca D. PhD, "OncoLog Volume 45, Number 07/08, July/
August 2000" (2000). OncoLog MD Anderson's Report to Physicians (All issues). 81.
https://openworks.mdanderson.org/oncolog/81

This Newsletter is brought to you for free and open access by the OncoLog MD Anderson's Report to Physicians at
OpenWorks @ MD Anderson. It has been accepted for inclusion in OncoLog MD Anderson's Report to Physicians
(All issues) by an authorized administrator of OpenWorks @ MD Anderson. For more information, please contact
rml-help@mdanderson.org.

REPORT TO
PHYSICIANS

'

JULY/AUGUST 2000
L45, N0.7/8

LNIVERSITYOFTEXAS

lvffiAN)ERSON

CANCER CENTER

Making Cancer Histor y-

5

2

Oinical Trials

Included are studies
of nonablative allogeneic transplants and
treatment of graftversus-host disease.

Caregiver's 1'o-:Do list

Taking care of
someone with cancer? House Call offers
suggestions for meeting your own needs.

Umbilic.al Cord
Blood Transplants

An alternative source
of stem cells may
allow more patients to
undergo transplants.
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Protecting
Young Donors

Who decides if a
child is capable of
donating blood or
bone marrow?

MDAnderson
Advances Allow Expanded Use of
Allogeneic Stem Cell Transplantation
by Kerry l. Wright

he tendency of trans
planted stem cells
to attack their
recipient's cancer
makes allogeneic transplants
more likely than autologous
transplants to cure disease,
but when this cell-<m-cell
activity is directed toward
normal cells, it can also
lead to graft-versus-host
disease (GVHD).

In the past, the threat
of GVHD limited the
number of patients
who were able to
undergo allogeneic
transplantation, but

Dr. Sergio Giralt (amter)
and Dr. Issa Khouri
·aht), associate projes
:s in the Department
of Blood and Marrow
Transplantation, talk
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thanks to advances in immunosup
pressive therapies and cell manipula
tion techniques, that number has
been steadily increasing.
"In the beginning, bone marrow
transplants were viewed as a way to
give very high doses of chemotherapy
and radiation, and the transplant
itself was considered supportive care

to help people recover from what
would otherwise be permanent
destruction of their bone marrow,"
said Richard E. Champlin, M.D.,
chairman of the Department of
Blood and Marrow Transplantation
at The University of Texas M. D.
Anderson Cancer Center. The
(Continued on next page)

lhe major advantage of
umbilical cord blood
transplantation is that
transplant recipients can
tolerate some mismatches
in HLA type.
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. ..
ring a recent follow-up visit�essor in the Department of
Clinical Pediatri.cs, poses with_, an umbilical cord bl.ood
transplant recipient. Since 1996, umbilical cord bl.ood transplantation has been an
oj>tion at M. D. Anderson for patients who do not have a related ste-m cell donor:
the greatest threat to patients.
"The reported incidence of fatal
complications in umbilical cord
blood transplants exceeds 30% in
the first 100 days," said Dr. Chan.
The small number of stem cells
contained in umbilical cord blood
has also limited transplant recipients
to children and low-weight adults,
but a new protocol at M. D. Ander
son aims to expand umbilical cord
blood transplantation to more adults
by combining umbilical cord blood
from two or three donors and trans
planting it into a single patient.
"In adult singlMonor umbilical
cord blood transplants, especially
when the HLA mismatch is large,
the engrafting is very delayed," said
areas de Lima, M.D., an assistant
ofessor in the Department of
Blood and Marrow Transplantation
and principal investigator of the
study. "The majority of cases will
en graft, but instead of the usual l 0

to 20 days for bone marrow and
blood stem cell transplants, umbilical
cord blood transplants may take 40 to
60 days to engraft," said Dr. de Lima.
Dr. de Lima hypothesizes that
combining umbilical cord blood
donors will increase the number
of stem cells available and decrease
the time it takes for the transplant to
engraft. This hypothesis is supported
by preclinical animal experiments.
While there have been verbal reports
of this type of study elsewhere, there
have been no published results.
Dr. de Lima stressed that the
protocol is an option for patients
who otherwise would not be able
to receive a transplant of any kind.
"The major eligibility criteria for
this protocol is patients who don't
have an available bone marrow or
blood stem cell donor," Dr. de Lima
said. 'This treatment is very inten
sive, so it's mainly for patients age
50 and younger."

While no results are yet available
from Dr. de Lima's study, the overall
survival rate reported worldwide in
the literature for both pediatric and
adult single-donor umbilical cord
blood transplant recipients is only
about40%
With an overall success rate of
56%, Dr. Chan and his colleagues
haYe so far had better results, due, in
part, to a modification in approach.
In most centers where pediatric
umbilical cord blood transplants
are performed, patients are given
antithymocyte globulin (ATC),
an immunosuppressive drug, to
prevent rejection. At M. D. Ander
son, melphalan and fludarabine are
used instead, and tacrolimus is used
in place of cyclosporin to prevent
graft-versus.host disease. Also, the
protocol at M. D. Anderson calls for
about 50% less radiation than most
protocols at other institutions, said
Dr. Chan.
Because the experiences of other
centers with umbilical cord blood
transplants have not been as favor
able, Dr Chan said, most prefer
to use unrelated bone marrow
transplants or other methods.
"Our success rate is such that we
encourage umbilical cord blood
transplants to be done," he said.
"Our approach is different."•
contact Dr: Chan
at (713) 792-7751 or Dr: de Lima at
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